HeartSciences Inc. (HSCS) Stock

HeartSciences Inc. (HSCS) is a Healthcare stock trading at $2.12 (as of 2026-08-07), with a market capitalization of $8.27M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

HeartSciences Inc. develops AI-enhanced electrocardiography offerings, including an algorithm intended to identify impaired cardiac relaxation and related dysfunction, as well as the MyoVista wavECG device that captures resting 12-lead ECG data. It also provides MyoVista Insights, a cloud platform for deploying AI-ECG algorithms across ECG hardware, serving clinical and diagnostic use cases.

Understand HeartSciences Inc.: how it makes money

HeartSciences applies AI to electrocardiography (ECG) to expand diagnostic usefulness, selling AI-enhanced ECG solutions that include the MyoVista wavECG device and MyoVista Insights (a cloud-based platform to host AI-ECG).

Its profit potential is tied to a layered offering, an AI-ECG algorithm plus a specific resting 12-lead ECG device (MyoVista wavECG), and a separate cloud platform (MyoVista Insights) that hosts the AI-ECG.

Business quality (Weak): The business description is specific, but no official reportable segments or operating KPIs were provided, limiting visibility into how operational performance is measured.

Bull case

  • Product focus on AI-enhanced ECG: The company develops AI-ECG solutions designed to detect impaired cardiac relaxation or cardiac dysfunction, using both AI-ECG information and conventional ECG information in the same test.
  • Platform plus device approach: It pairs a resting 12-lead ECG device (MyoVista wavECG) with MyoVista Insights, a cloud-based platform to host AI-ECG.
  • Reported gross margin: For the period 2025-10-31, gross margin was 58.3%.

Bear case

  • Significant operating losses: For the period 2025-10-31, operating margin was -85713.2%, indicating losses at the operating level.
  • Limited disclosed operating metrics and segmentation: No official reportable segments or operating KPI labels were provided, which makes it harder to track which part of the business drives results.
  • Reported revenue shows as 0.0B in the provided data: Revenue for 2025-10-31 is shown as 0.0B in the provided facts, which creates uncertainty in interpreting scale from this dataset.
Valuation — source: SEC EDGAR (first-party)
Price$2.12
Market Cap$8.27M
Price / Book36.57
Price / Sales1900.44
FCF Yield-141.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$4319.00
Net Margin-211666.5%
Return on Equity-4044.0%
Current Ratio0.53
Revenue Growth (YoY)-0.7%
EPS Growth (YoY)-62.7%
FCF Growth (YoY)0.2%
Financial Health — source: SEC EDGAR
Altman Z-Score-27.49 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderTFB Advisors LLC ($74766.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOAndrew Simpson
Employees15
CountryUS
IPO Date2022-06-16

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Nutriband Inc. (NTRB)
  • Milestone Scientific Inc. (MLSS)
  • Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)
  • Co-Diagnostics, Inc. (CODX)
  • Picard Medical, Inc. (PMI)
  • ENvue Medical, Inc. (FEED)
  • CollPlant Biotechnologies Ltd. (CLGN)
  • Bone Biologics Corporation (BBLG)
HSCS earnings history · HSCS institutional & insider holders · HSCS KPIs & operating metrics · HSCS financials · HSCS investor presentations & press releases · HSCS SEC filings · HSCS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-07.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.